T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2751
ZipRecruiter
ZIP
$388M
| $230K | ﹤0.01% |
58,678
+7,339
| +14% | +$33K |
|
2752
Cerus
CERS
$572M
| $229K | ﹤0.01% |
111,048
+17,770
| +19% | +$30.8K |
|
2753
Enanta Pharmaceuticals
ENTA
$391M
| $228K | ﹤0.01% |
14,410
+4,264
| +42% | +$54.2K |
|
2754
Frequency Electronics
FEIM
$856M
| $228K | ﹤0.01% |
+4,223
| New | +$155K |
|
2755
Lands' End
LE
$390M
| $228K | ﹤0.01% |
15,651
-464
| -3% | -$7.16K |
|
2756
Mastech Digital
MHH
$95.3M
| $228K | ﹤0.01% |
32,598
| – | – |
|
2757
Orion Group Holdings
ORN
$392M
| $228K | ﹤0.01% |
22,937
+3,450
| +18% | +$33.4K |
|
|
RZLV
2758
Rezolve AI
RZLV
$1.06B
| $228K | ﹤0.01% |
88,472
+9,902
| +13% | +$37.4K |
|
|
CWBC
2759
Community West Bancshares
CWBC
$706M
| $225K | ﹤0.01% |
+9,957
| New | +$218K |
|
|
ACH
2760
Accendra Health
ACH
$84.6M
| $224K | ﹤0.01% |
79,908
+14,079
| +21% | +$50.3K |
|
|
CVGW
2761
DELISTED
Calavo Growers
CVGW
| $223K | ﹤0.01% |
10,207
-7,804
| -43% | -$173K |
|
2762
Savers
SVV
$1.67B
| $223K | ﹤0.01% |
23,869
+3,288
| +16% | +$33.8K |
|
2763
ARKO Corp
ARKO
$505M
| $221K | ﹤0.01% |
48,596
+7,901
| +19% | +$35.4K |
|
|
DRUG
2764
Bright Minds Biosciences
DRUG
$765M
| $221K | ﹤0.01% |
+2,830
| New | +$189K |
|
2765
Standard BioTools
LAB
$294M
| $221K | ﹤0.01% |
172,134
+14,592
| +9% | +$19.6K |
|
2766
RBB Bancorp
RBB
$466M
| $221K | ﹤0.01% |
+10,682
| New | +$210K |
|
2767
Zumiez
ZUMZ
$319M
| $221K | ﹤0.01% |
+8,462
| New | +$203K |
|
2768
Stereotaxis
STXS
$137M
| $220K | ﹤0.01% |
95,221
+10,235
| +12% | +$27.3K |
|
2769
Bridgewater Bancshares
BWB
$620M
| $218K | ﹤0.01% |
12,419
+1,535
| +14% | +$26.6K |
|
2770
Natural Gas Services Group
NGS
$474M
| $218K | ﹤0.01% |
+6,472
| New | +$193K |
|
2771
Riley Exploration Permian
REPX
$786M
| $215K | ﹤0.01% |
+8,138
| New | +$216K |
|
2772
Custom Truck One Source
CTOS
$2.33B
| $212K | ﹤0.01% |
36,695
+4,898
| +15% | +$29.9K |
|
2773
First Bank
FRBA
$471M
| $212K | ﹤0.01% |
12,857
+1,438
| +13% | +$23K |
|
|
STKL
2774
DELISTED
SunOpta
STKL
| $211K | ﹤0.01% |
55,349
+5,223
| +10% | +$23.7K |
|
2775
Verastem
VSTM
$604M
| $211K | ﹤0.01% |
27,236
-550,796
| -95% | -$4.91M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.